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Summary
BACKGROUND: Patients who have acute coronary syn-
dromes with or without ST-segment elevation have high
rates of major vascular events. We evaluated the efficacy
of early clopidogrel administration (300 mg) (<24 hours)
when given with aspirin in such patients.
METHODS: We included 30,243 patients who had an
acute coronary syndrome with or without ST segment elev-
ation. Data on early clopidogrel administration were avail-
able for 24,463 (81%). Some 15,525 (51%) of the total
cohort were administrated clopidogrel within 24h of admis-
sion.
RESULTS: In-hospital death occurred in 2.9% of the pa-
tients in the early clopidogrel group treated with primary
PCI and in 11.4% of the patients in the other group without
primary percutaneous coronary intervention (PCI) and no
early clopidogrel. The unadjusted clopidogrel odds ratio
(OR) for mortality was 0.31 (95% confidence interval
0.27–0.34; p <0.001). Incidence of major adverse cardiac
death (MACE) was 4.1% in the early clopidogrel group
treated with 1°PCI and 13.5% in the other group without
primary PCI and no early clopidogrel (OR 0.35, confidence
interval 0.32–0.39, p <0.001). Early clopidogrel adminis-
tration and PCI were the only treatment lowering mortality
as shown by mutlivariate analysis.
CONCLUSIONS: The early administration of the anti-
platelet agent clopidogrel in patients with acute coronary
syndromes with or without ST-segment elevation has a
beneficial effect on mortality and major adverse cardiac
events. The lower mortality rate and incidence of MACE
Abbreviations
ACS Acute Coronary Syndrome
PCI Percutaneous Coronary Intervention
ASA Acetyl Salicylic Acid
MACE Major Adverse Cardiac Event (death, re-infarction, stroke)
MM medically managed patients (patients not receiving PCI)
STEMI ST segment Elevation Myocardial Infarction
NSTEMI Non-ST segment Elevation Myocardial Infarction
OR Odds ratio
emerged with a combination of primary PCI and early clop-
idogrel administration.
Key words: acute coronary syndrome; clopidogrel; STEMI
Introduction
Current treatment guidelines issued by the European So-
ciety of Cardiology (ECS) and the American Heart As-
sociation (AHA) recommend that, unless contraindicated,
a combination therapy that includes acetyl salicylic acid
(ASA) and clopidogrel should be administered to acute
coronary syndrome (ACS) patients with non-ST segment
elevation (NSTEMI) [1] as well as to ACS patients with
STEMI [2]. This treatment is important in preventing short-
term mortality after the first event and acts prophylactically
for later major adverse cardiac events (MACE), even when
no immediate percutaneous coronary intervention (PCI) is
performed [3].
A 2008 analysis of data gathered between January 2001
and December 2005 from a large US registry has shown
not only that clopidogrel administration to NSTEMI pa-
tients immediately after hospital admission significantly re-
duces in-hospital mortality, but that, even as late as 2005,
a considerable portion of patients in the USA were not re-
ceiving treatment that fully complied with acknowledged
guidelines [4]. Positive clinical benefit for clopidogrel use
has been demonstrated for patients undergoing PCI [5]; fur-
thermore, significantly lower 1-year cardiovascular mortal-
ity rates were reported in Canada when prescription rates
increased after reimbursement authorisation [6]. At the
same time, results from a smaller French registry suggest
that the clinical outcome after one year does not signific-
antly differ for NSTEMI and STEMI patients [7].
The aim of this study was to obtain further evidence of the
clinical benefit of guideline adherence in terms of mortality
and MACE in Switzerland, and to investigate compliance
with treatment guidelines.
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Methods
AMIS (Acute Myocardial Infarction in Switzerland) Plus
is a national Swiss registry for patients with acute coronary
syndrome (STEMI, NSTEMI, and unstable angina). AMIS
is hosted by the Institute of Social and Preventive Medicine
at the University of Zurich (now termed AMIS Plus with
enhanced data collection). Emphasis is placed on the eval-
uation of risk factors (family history of coronary artery
disease (CAD), diabetes, hypertension, dyslipidemia,
smoking), diagnostics, urgent therapy strategies, treatment
and long-term outcome of acute coronary syndrome. All
data acquisition and analysis tasks are performed in strict
accordance with Good Clinical Practice (GCP) guidelines.
Details have been described elsewhere [8] and are available
from http://www.amis-plus.ch. Data are entered in a web-
database at the time of hospitalisation. MACE were defined
as death, myocardial infarction or re-infarction and stroke.
This investigation uses the data from all ACS patients en-
rolled in the AMIS Plus. The data analysed focused on
the impact of clopidogrel, given within 24 hours of ad-
mission, on mortality and MACE. Observed treatment re-
gimens were also compared with established treatment
guidelines. MACE were defined as composed end points of
re-infarction, cerebrovascular events and/or death. The null
hypothesis tested was that there is no difference in mortal-
ity and MACE because of early clopidogrel administration.
Statistical analysis
The AMIS data centre uses SPSS software for data analysis
(SPSS Inc., Chicago, Illinois; Version 17.0). Proportions
were compared using Fisher's Exact Test. Odds ratio (OR)
with 95% confidence interval were calculated (16). All
statistical tests were two-sided. A p value <0.05 was con-
sidered significant. A multivariate logistic regression mod-
el based on backwards logistic regression methodology
was used to determine in-hospital mortality predictors from
the following set of variables: age, sex, Killip classes, prior
CAD, diabetes current smoking, clopidogrel, primary PCI
and resuscitation prior admission.
Results
Demography
The registry included data from 30,243 ACS patients from
76 Swiss hospitals. For 24,463 (81%) of these patients, data
on early clopidogrel (<24 h of admission) administration
were available (fig. 1). Some 15,525 (51%) of the total co-
hort were administrated clopidogrel within 24h of admis-
Figure 1
Flow chart of the patient regarding STEMI, NSTEMI and PCI or no
PCI and percentage of patients treated with clopidogrel ( C ).
sion (table 1). Patients receiving early clopidogrel treat-
ment (300 mg loading dose followed by 75 mg/day) were
significantly younger (mean age 64 years vs. 69 years, p
<0.001), there were more smokers (40%, vs. 33%, p
<0.001), and more males (76 vs. 67%, p <0.001). A total
of 4.7% of the patients of the early clopidogrel group were
in Killip class III and IV versus 10% of the other group (p
<0.001; table 1). Of note, aspirin was given to all patients
and almost 2/3 them had a body mass index above 25. A
total of 48% of Swiss patients did not receive primary PCI
(including dilation of coronary arteries) and are henceforth
termed MM (medically managed) patients.
Mortality and MACE (figure 1)
Early clopidogrel administration is beneficial for 24h mor-
tality, in-hospital mortality and MACE as shown in table 2
and figure 1.
Multivariate analysis shows that some clinical parameters
were associated with an increased mortality (table 4). Early
clopidogrel administration and PCI were the only treatment
that lowered mortality as shown by this analysis.
STEMI patients
In-hospital mortalities were similar but slightly higher for
patients with primary PCI (8.0%) alone when compared
to early clopidogrel alone (6.8%) (p =0.24). MACE were
equally frequent between primary PCI patients without
early clopidogrel and patients without primary PCI but
early clopidogrel administration (10% versus 9.3%, p =
0.55).
Non STEMI patients
Mortality was similar for patients with primary PCI and no
clopidogrel (3.4%) and patients without primary PCI and
early clopidogrel administration (3.2%, p = 0.82). MACE
were more frequent in patients without early clopidogrel
and 1°PCI versus no primary PCI and early clopidogrel
treatment (5.2% versus 4.2%, p = 0.26). In both STEMI
and non-STEMI the lower mortality rate and incidence of
MACE emerged from the group of patients treated with a
Figure 2
Effect of early clopidogrel administration (within 24h of admission)
on 24h mortality, in-hospital mortality, and MACE. The effect of
clopidogrel is statistically significant with p < 0.0001 in Fisher's
exact test in all categories..
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combination of primary PCI and early clopidogrel admin-
istration (table 3).
Discussion
The AMIS Plus registry with its large database on treat-
ments and outcomes provides a comprehensive picture of
AMI management and its development over the years in
Switzerland. However, when statistical comparisons are
made between therapy dependent outcomes, one must al-
ways keep in mind that treatments are not randomised: they
are assigned by the treating physicians in a real-world en-
vironment according to an individual assessment based on
the patient's particular situation and the facilities offered by
the admitting hospital. Baseline comparability of patients
receiving different treatments is therefore not ensured, and
extensive multivariate analyses for predictors would have
to be conducted in order to produce stand-alone valid stat-
istical results. The extent of these differences with respect
to early clopidogrel administration in terms of demograph-
ic properties, pre-existing pathologies, and previous treat-
ments is shown in table 1. The prevalence of the individual
Table 1: Clopidogrel as immediate therapy in patients admitted for acute coronary syndrome between 2000 and 2008.
Clopidogrel no (n = 8,978) Clopidogrel yes (n = 15,525) p
Gender male 6,006/8,978 (66.9) 11,774/15,525 (75.8) <0.001
Age in years range
mean (SD)
22-101
69.0 (13.6)
21-99
63.6 (12.7)
<0.001
Diabetes 1,972/8,594 (22.9) 2,731/14,914 (18.3) <0.001
Current smoking 2690/8199 (32.8) 5,878/14,557 (40.4) <0.001
Hypertension 5,254/8,443 (62.2) 8,619/14,810 (58.2) <0.001
Dyslipidemia 4,447/7,694 (57.8) 8,259/13,983 (59.1) 0.072
Overweight (BMI >25) 4,633/7,474 (62.0) 8,664/13,202 (65.6) <0.001
Killip classes n 8,940 15,450 <0.001
I–II 8,040 (89.9) 14,725 (95.3)
III–IV 900 (10.1) 725 (4.7)
Regular medication before admission
Aspirin, ASA 3,603/8,775 (41.1) 5,758/15,117 (38.1) <0.001
Clopidogrel* 119/2,838 (4.2) 1,262/10,060 (12.5) <0.001
Oral anticoagulant 808/8,740 (9.2) 665/15,000 (4.4) <0.001
Beta-blocker 2,867/8,737 (32.8) 4,579/15,032 (30.5) <0.001
ACE inhibitor or Angiotensin II receptor
antagonist
2,862/8,744 (32.7) 4,654/15,046 (30.9) 0.004
Ca-channel blocker 1,248/8,670 (14.4) 1,840/14,952 (12.3) <0.001
Nitrates 1,324/8,724 (15.2) 1,263/14,978 (8.4) <0.001
Diuretics 2,279/8,749 (26.0) 2,465/15,016 (16.4) <0.001
Statins 2,077/8,732 (23.8) 4,237/15,063 (28.1) <0.001
Table 2a: Isolated effect of early clopidogrel treatment on clinical outcome.
N OR 95% CI p
24 h mortality 24,487 0.20 0.16–0.24 <0.0001
In-hospital mortality 24,503 0.31 0.27–0.34 <0.0001
MACE 24,036 0.35 0.32–0.39 <0.0001
Table 2b: Effect of early clopidogrel treatment, adjusted for age, gender and STEMI.
N OR 95% CI p
24 h mortality 24,447 0.25 0.20–0.31 <0.0001
In-hospital mortality 24,463 0.41 0.36–0.46 <0.0001
MACE 23,996 0.45 0.40–0.49 <0.0001
Table 3: In-hospital mortality and MACE. All proportions are statistically significantly different with respect to early clopidogrel administration (p <0.0001, Fisher's exact
test).
In-hospital mortality STEMI
Clopidogrel
NSTEMI
Clopidogrel
All
Clopidogrel
Yes No Yes No Yes No
All 370/9,099; 4.1% 568/4,581; 12.4% 154/6,409; 2.4% 352/4,374; 8.0% 528/15,525; 3.4% 926/8,978; 10.3%
1°PCI 246/7,275; 3.4% 87/1,090; 8.0% 62/3,560; 1.7% 25/732; 3.4% 310/10,833; 2.9% 112/1,828; 6.1%
No 1°PCI 124/1,824; 6.8% 481/3,491; 13.8% 92/2,837; 3.2% 326/3,625; 9.0% 218/4,669; 4.7% 813/7,126; 11.4%
MACE STEMI
Clopidogrel
NSTEMI
Clopidogrel
All
Clopidogrel
Yes No Yes No Yes No
All 5.7% 14.6 % 3.4% 9.9% 4.7% 12.3%
1°PCI 4.8% 10.0 % 2.8% 5.2% 4.1% 8.1%
No 1°PCI 9.3% 16.1 % 4.2% 10.8% 6.2% 13.5%
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risk factors, even smoking, was closely similar to what has
been reported in the OPERA study [13], except for hy-
pertension, which was lower in the French investigation
(47%). It remains open whether the same blood pressure
limits were applied. Our numbers are almost identical for
STEMI (29% vs. 29%) and lower for NSTEMI patients
(27% vs. 48%) as those reported in the OPERA study [13].
Despite the methodological shortcomings, strong and con-
sistent positive results concerning mortality and, similarly,
MACE, cannot possibly be explained by those differences
found between the treatment groups cited above. For all
ACS patients, the best results are thus achieved with ASA
and early clopidogrel, and, when indicated, in combina-
tion with primary PCI. Clopidogrel consistently reduces the
incidence of mortality as well as MACE for all ACS pa-
tients. This was shown when clopidogrel was given in ad-
dition to aspirin, like in the CURE [7, 9] CREDO [10] and
COMMIT [11] trials. Our results confirm these observa-
tions and emphasise the need of early clopidogrel adminis-
tration and primary PCI. Similar data were recently repor-
ted from the GRACE [12] registry with a significant benefit
of dual anti-platelet therapy for patients with NSTEMI.
These authors, also, conclude to an underuse of this
strategy especially in Canadian patients [13]. The obser-
vation made in the OPERA [14] study that the outcome
after one year is not significantly different for STEMI and
NSTEMI cannot be confirmed by the AMIS Plus data.
The finding that NSTEMI patients are less likely to receive
early clopidogrel treatment can, to a degree, be explained
by the economic pressure exerted by health authorities, and
the opinion that these patients are at a lower risk for recur-
ring cardiovascular events. Caution should be applied here
in view of the 12-month risk reported in the OPERA study
[14] From 2002 to 2005, early clopidogrel administration
in Switzerland was closely similar to the levels reported
from the CRUSADE study [4] (i.e., 30–50%). It can be
noted with satisfaction that adherence to the recommenda-
tions stipulated by the acknowledged treatment guidelines
has significantly improved in recent years, and continues
to improve with each passing year. However under use of
clopidogrel has recently been reported in the GRACE re-
gistry [13] showing that efforts should still be made to in-
crease these numbers. Treatment guidelines are, in gener-
al, followed better in hospitals with catheter labs (which
are usually larger and more centrally located), though
guideline adherence has increased with time in recent years
in all hospitals.
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OR 95% CI p
Gender 1.01 0.86–1.18 0.93
Killip I
Killip II
Killip III
Killip IV
Ref.
2.39
4.52
17.77
2.00–2.84
3.60–5.68
13.42–23.54
<0.001
<0.001
<0.001
Prior CAD 1.02 0.87–1.18 0.83
Diabetes 1.30 1.10–1.54 0.002
Current smoking 1.16 0.96–1.39 0.115
Clopidogrel 0.57 0.48–0.69 <0.001
Age 1.07 1.06–1.08 <0.001
Primary PCI 0.70 0.57–0.87 = 0.001
Resuscitation 4.98 3.86–6.44 <0.001
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Figures (large format)
Figure 1
Flow chart of the patient regarding STEMJ, NSTEMJ and PCI or no PCI and wpercentage of patients treated with clopidogrel ( C ).
Figure 2
Effect of early clopidogrel administration (within 24h of admission) on 24h mortality, in-hospital mortality, and MACE. The effect of clopidogrel is
statistically significant with p < 0.0001 in Fisher's exact test in all categories..
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